Gharaibeh EZ et al., 2018-10-22: Case report of a 64-year-old with relapsed double-hit DLBCL who received a secondary-prevention regimen of thiamine, methylene blue 50 mg IV every 6 hours and hydration before the next ifosfamide cycle.
Prior to initiating cycle 2 of R-IE, she was started on prophylactic oral thiamine 100 mg, once a day, one week prior to her admission, methylene blue 50 mg intravenous every 6 h (for a total of four doses) and intravenous hydration with normal saline starting on day one of admission.
Gharaibeh EZ et al., 2018-10-22: Case report of a 64-year-old with relapsed double-hit DLBCL who received a secondary-prevention regimen of thiamine, methylene blue 50 mg IV every 6 hours and hydration before the next ifosfamide cycle. C6 (published dose). Study type: single case report (J Oncol Pharm Pract 2019;25:1784-1786); University of Cincinnati per journal listing, USA. N=1, female, 64 years. Regimen quoted in full: oral thiamine 100 mg daily starting one week before admission; methylene blue 50 mg IV every 6 hours for four doses; IV normal saline from day one; ifosfamide 2000 mg/m2 days 1-3 as a 24-hour continuous infusion. She developed only mild encephalopathy on the last dose, which resolved without intervention. Funder/conflicts not stated in the PubMed record. Comparator: her own prior cycle. Study type: case report.
